Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 10;19(6):709-718.
doi: 10.6004/jnccn.2020.7653.

Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study

Dominik J Ose  1   2 , Richard Viskochil  2 , Andreana N Holowatyj  2   3   4 , Mikaela Larson  2   3 , Dalton Wilson  2 , William A Dunson  2 , Vikrant G Deshmukh  5 , J Ryan Butcher  3 , Belinda R Taylor  6 , Kim Svoboda  6 , Jennifer Leiser  1 , Benjamin Tingey  1 , Benjamin Haaland  2   3 , David W Wetter  2   3 , Simon J Fisher  7 , Mia Hashibe  1   2 , Cornelia M Ulrich  2   3
Affiliations

Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study

Dominik J Ose et al. J Natl Compr Canc Netw. .

Abstract

Background: This study aimed to understand the prevalence of prediabetes (preDM) and diabetes mellitus (DM) in patients with cancer overall and by tumor site, cancer treatment, and time point in the cancer continuum.

Methods: This cohort study was conducted at Huntsman Cancer Institute at the University of Utah. Patients with a first primary invasive cancer enrolled in the Total Cancer Care protocol between July 2016 and July 2018 were eligible. Prevalence of preDM and DM was based on ICD code, laboratory tests for hemoglobin A1c, fasting plasma glucose, nonfasting blood glucose, or insulin prescription.

Results: The final cohort comprised 3,512 patients with cancer, with a mean age of 57.8 years at cancer diagnosis. Of all patients, 49.1% (n=1,724) were female. At cancer diagnosis, the prevalence of preDM and DM was 6.0% (95% CI, 5.3%-6.8%) and 12.2% (95% CI, 11.2%-13.3%), respectively. One year after diagnosis the prevalence was 16.6% (95% CI, 15.4%-17.9%) and 25.0% (95% CI, 23.6%-26.4%), respectively. At the end of the observation period, the prevalence of preDM and DM was 21.2% (95% CI, 19.9%-22.6%) and 32.6% (95% CI, 31.1%-34.2%), respectively. Patients with myeloma (39.2%; 95% CI, 32.6%-46.2%) had the highest prevalence of preDM, and those with pancreatic cancer had the highest prevalence of DM (65.1%; 95% CI, 57.0%-72.3%). Patients who underwent chemotherapy, radiotherapy, or immunotherapy had a higher prevalence of preDM and DM compared with those who did not undergo these therapies.

Conclusions: Every second patient with cancer experiences preDM or DM. It is essential to foster interprofessional collaboration and to develop evidence-based practice guidelines. A better understanding of the impact of cancer treatment on the development of preDM and DM remains critical.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flowchart with exclusion criteria * Participants in the TCC cohort as of July 31, 2018
Figure 2:
Figure 2:
Patterns of diabetes and pre-diabetes among selected cancer types
See this image and copyright information in PMC

References

    1. National Cancer Institute, Division of Cancer Control and Population Science. Office of Cancer Survivorship: Statistics. https://cancercontrol.cancer.gov/ocs/statistics/statistics.html#ref1. Accessed October 5, 2019.
    1. American Diabetes Association. National Diabetes Statistics Report, 2017. Atlanta: GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-stat.... Accessed September 2, 2019.
    1. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-0666. - DOI - PMC - PubMed
    1. Zaorsky NG, Shaikh T, Ruth K, et al. Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy. Clin Genitourin Cancer. 2017;15(2):326–335.e3. doi:10.1016/j.clgc.2016.08.020. - DOI - PMC - PubMed
    1. Raikundalia MD, Fang CH, Spinazzi EF, et al. Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Surgery. Otolaryngol Head Neck Surg. 2016;154(2):294–299. doi:10.1177/0194599815607852. - DOI - PubMed

Publication types